USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: NovoBiotic Pharmaceuticals, LLC
Address: 767C Concord Avenue
Cambridge, MA 02138-1044
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,612,261.00 8
SBIR Phase II $14,377,352.00 4

Award List:

Developing Novel Antibiotics Against Yersinia pestis

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Losee L. Ling
Award Amount: $471,409.00
Abstract:
DESCRIPTION (provided by investigator): The overall goal of this project is to develop therapies against Yersinia pestis, the causative agent of plague and one of the most dangerous potential bioweapons. We recently developed a general method to grow previously "unculturable" microorganisms… More

Novel Approaches to Accessing Secondary Metabolites

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrew L. Staley
Award Amount: $999,578.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop novel therapeutic agents against Yersinia pestis, the causative agent of plague and one of the most dangerous potential bioweapons. In this exploratory project, we will develop novel approaches to obtain previously… More

Developing Novel Antibiotics Against Yersinia pestis

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Losee L. Ling
Award Amount: $5,412,779.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to develop broad-spectrum antibiotics against Yersinia pestis and other important human pathogens. The potential use of engineered, multi-drug-resistant strains as agents of bioterrorism necessitates the development of new… More

Isolating novel fungi for antibiotic discovery

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Charles M. Moore
Award Amount: $598,516.00
Abstract:
DESCRIPTION (provided by applicant): The long term goal of this project, is to develop novel antibiotics active against clinically important multi-drug- resistant (MDR) bacterial pathogens such as methicillin resistant Staphylococcus aureus (MRSA), and hig hly drug resistant Gram negative pathogens… More

Isolating novel actinomycetes for antibiotic discovery

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Charles M. Moore
Award Amount: $598,617.00
Abstract:
DESCRIPTION (provided by applicant): An increase in the incidence of infections caused by drug resistant pathogens coupled to the need to develop antibacterial countermeasures against bioterror agents has resulted in a critical need for the development of new dual-use antibiotics. The goal of this… More

Isolating novel actinomycetes for antibiotic discovery

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Losee L. Ling
Award Amount: $2,998,355.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to discover novel broad-spectrum antibiotics acting against critically important human pathogens. The unmet need is especially acute for Gram negative pathogens, where we are rapidly running out of options for treating multidrug… More

Drug Discovery from Slow Growing and Rare Microbial Species

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amy Spoering
Award Amount: $598,976.00
Abstract:
DESCRIPTION (provided by applicant): Multidrug resistant organisms are increasingly prevalent in nosocomial and community settings. Novel antibiotics with new mechanisms of action are needed to combat the impending public health crisis of antibiotic-resist ant pathogens like Staphylococcus aureus,… More

Isolating novel fungi for antibiotic discovery

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: Losee L. Ling
Award Amount: $2,998,501.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to discover and develop novel broad-spectrum antibiotics acting against critically important human pathogens. The unmet need is especially acute for Gram-negative pathogens, where we are rapi dly running out of options for treating… More

High throughput antibiotic discovery from the uncultivated microbial majority.

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Amy Spoering
Award Amount: $597,943.00
Abstract:
DESCRIPTION (provided by applicant): The long-term goal of this project is to develop novel, broad-spectrum antibiotics against both biowarfare agents and common drug resistant pathogens. The potential use of engineered, multi-drug-resistant strains as age nts of bioterrorism, and the current spread… More

UV-Based Approach for Accessing New Antibiotics

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Losee L. Ling – 617-864-2880
Award Amount: $599,946.00
Abstract:
DESCRIPTION (provided by applicant): The goal of this project is to discover novel antibiotics by activating the silent biosynthetic operons of Actinobacteria. Whole genome sequencing of many Actinobacteria showed that there are 10-20 times more operons coding for secondary metabolites than known… More

Drug Discovery from Slow Growing and Rare Microbial Species

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Amy Spoering – 857-928-5616
Award Amount: $2,967,717.00
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this project is to discover novel antibiotics to combat important drug-resistant pathogens. We are running out of treatment options for pathogens such as S. aureus MRSA, vancomycin-resistant Enterococci (VRE), multidrug-resistant P.… More

SBIR Phase I: Novel Antibiotics from Marine Animal-Microbe Symbioses

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: NSF
Principal Investigator: Dallas Hughes
Award Amount: $147,276.00
Abstract:
This Small Business Innovation Research (SBIR) Phase I project will develop a new platform technology to exploit previously inaccessible microbial diversity to discover novel broad-spectrum antibiotics. The project focuses on symbioses between marine invertebrates and microorganisms known to be rich… More